Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience

Yesilipek, M.; Uygun, Vedat; Kupesiz, OSMAN; Karasu, Gulsun; Ozturk, Gulyuz; Ertem, Mehmet; Sasmaz, Ilgen; Daloglu, Hayriye; Güler, ELİF; Hazar, Volkan; Fisgin, Tunc; Sezgin, Gülay; Kansoy, Savaş; Kuşkonmaz, Bülent; Akinci, Burcu; Ozbek, Namik; Ince, Elif; Ozturkmen, Seda; Tayfun Küpesiz, FUNDA; Yalcin, KORAY; Anak, Sema; Bozkurt, Ceyhun; Karakükcü, Musa; Küpeli, Serhan; Albayrak, Davut; Oniz, Haldun; Aksoylar, Serap; Okur, Fatma; Albayrak, Canan; Demir Yenigürbüz, Fatma; Bozkaya, Ikbal; Ileri, Talia; Gursel, Orhan; Karagun, Barbaros; Tüysüz Kintrup, GÜLEN; Celen, Suna; Elli, Murat; Aksoy, Basak; Yılmaz, Ebru; Tanyeli, Atila; Akyol, Sule; Sivi, Zuhal; Özek, Gülcihan; Çetinkaya, Fahriye; Kartal, İbrahim; Atay, Didem; Akyay, Arzu; Bilir, Ozlem; Cakmakl, Hasan; Kurekci, Emin; Malbora, Baris; Akbayram, Sinan; Demir, Haci; Kilic, Suar; Meral Güneş, Adalet; Zengin, Emine; Ozmen, Salih; Antmen, Ali

doi:10.1038/s41409-022-01613-w

Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience

Atıf İçin Kopyala

Yesilipek M. A., Uygun V., Kupesiz A., Karasu G., Ozturk G., Ertem M., ...Daha Fazla

BONE MARROW TRANSPLANTATION, cilt.57, sa.5, ss.760-767, 2022 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 57 Sayı: 5
Basım Tarihi: 2022
Doi Numarası: 10.1038/s41409-022-01613-w
Dergi Adı: BONE MARROW TRANSPLANTATION
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Agricultural & Environmental Science Database, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Sayfa Sayıları: ss.760-767
Akdeniz Üniversitesi Adresli: Evet

Özet

We report the national data on the outcomes of hematopoietic stem cell transplantation (HSCT) for thalassemia major (TM) patients in Turkey on behalf of the Turkish Pediatric Stem Cell Transplantation Group. We retrospectively enrolled 1469 patients with TM who underwent their first HSCT between 1988 and 2020 in 25 pediatric centers in Turkey. The median follow-up duration and transplant ages were 62 months and 7 years, respectively; 113 patients had chronic graft versus host disease (cGVHD) and the cGVHD rate was 8.3% in surviving patients. Upon the last visit, 30 patients still had cGvHD (2.2%). The 5-year overall survival (OS), thalassemia-free survival (TFS) and thalassemia-GVHD-free survival (TGFS) rates were 92.3%, 82.1%, and 80.8%, respectively. cGVHD incidence was significantly lower in the mixed chimerism (MC) group compared to the complete chimerism (CC) group (p < 0.001). In survival analysis, OS, TFS, and TGFS rates were significantly higher for transplants after 2010. TFS and TGFS rates were better for patients under 7 years and at centers that had performed over 100 thalassemia transplants. Transplants from matched unrelated donors had significantly higher TFS rates. We recommend HSCT before 7 years old in thalassemia patients who have a matched donor for improved outcomes.